中成药治疗成人社区获得性肺炎临床应用指南(2025版)  

Guideline on Treating Adult Community-acquired Pneumonia with Chinese Patent Medicines(2025 Edition)

作　　者：杨江 李建生[1,2] 陈耀龙[3] 刘辉国 王建新 喻佳洁[6] 李慧茹 肖琼华 谢洋[1,2] 李素云[1,2] 王明航[1,2] 代表编制组 YANG Jiang;LI Jiansheng;CHEN Yaolong;LIU Huiguo;WANG Jianxin;YU Jiajie;LI Huiru;XIAO Qionghua;XIE Yang;LI Suyun;WANG Minghang;Represented the Development Group(National Regional TCM(Lung Disease)Diagnostic and Treatment Center,the First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,China;Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province&Education Ministry of P.R.China,Zhengzhou 450046,China;China Evidence-Based Medicine Center,Lanzhou University,Lanzhou 730030,China;Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430030,China;Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100061,China;Cochrane China Center,West China Hospital,Sichuan University,Chengdu 610041,China;不详)

机构地区：[1]河南中医药大学第一附属医院国家区域中医(肺病)诊疗中心,河南省郑州市450000 [2]河南中医药大学呼吸疾病中医药防治省部共建协同创新中心,河南省郑州市450046 [3]兰州大学循证医学中心,甘肃省兰州市730030 [4]华中科技大学同济医学院附属同济医院,湖北省武汉市430030 [5]中国中医科学院西苑医院,北京市100061 [6]四川大学华西医院中国Cochrane中心,四川省成都市610041 [7]不详

出　　处：《中国全科医学》2025年第20期2464-2480,共17页Chinese General Practice

基　　金：国家重点研发计划“中医药现代化研究”重点专项(2023YFC3502602);国家中医药管理局中成药治疗优势病种标准化项目(SATCM-2015-BZ402-407);国家自然科学基金面上项目(82474483)。

摘　　要：社区获得性肺炎(CAP)是常见的感染性疾病之一,其发病率和病死率随年龄增长而上升,当前治疗面临诸多挑战。中成药治疗成人CAP疗效明确,但缺乏高质量循证指南。为此,课题组组织多学科专家,遵循“循证为主、共识为辅、经验为鉴”原则,参照临床实践指南研制规范,通过文献调研、德尔菲法问卷遴选出6个临床问题,系统检索并整合当前最佳循证证据。在综合评估证据质量、患者意愿、价值取向及资源配置等因素的基础上,通过两轮德尔菲调研及专家共识会议,最终形成《中成药治疗成人社区获得性肺炎临床应用指南(2022版)》,于2023年发表在Pharmacological Research。本次修订对证据进行了系统更新,新增药物经济性及推荐理由,共形成14条推荐意见,涵盖9种中成药,并依据首部中成药临床实践指南报告规范完成改编,以提升指南临床适用性、可及性及可操作性,促进中成药在成人CAP治疗中的合理使用。Community-acquired pneumonia(CAP),one of the common infectious diseases,exhibits increasing morbidity and mortality with age,posing significant clinical challenges. Although Chinese patent medicines(CPMs) demonstrate efficacy in adult CAP treatment,high-quality evidence-based guidelines have been lacking. To address this gap, we organized a multidisciplinary expert panel to develop the Guideline on Treating Community-acquired Pneumonia with Chinese Patent Medicines,adhering to the principles of evidence-based,consensus-supplemented,and experience-referred and following standardized clinical practice guideline development procedures. Through literature review and Delphi questionnaires, six clinical questions were identified. Systematic evidence retrieval and synthesis of the best available evidence were conducted, integrating factors such as evidence quality,patient preferences,value orientations,and resource allocation. After two rounds of Delphi surveys and expert consensus meetings,the guideline was finalized and published in 2023 in Pharmacological Research. This updated edition systematically incorporates recent evidence,adds pharmacoeconomic evaluations and recommendation rationales,and presents 14 recommendations covering nine CPMs,covers 9 kinds of traditional Chinese patent medicines. The guideline has been restructured according to the first edition of reporting checklist for Chinese patent medicine guidelines(RIGHT for CPM) to enhance clinical applicability,accessibility,and operationalizability,thereby promoting the rational use of CPMs in adult CAP treatment.

关 键 词：社区获得性肺炎 中成药 治疗 成人 指南 

分 类 号：R563.1[医药卫生—呼吸系统]